我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
招募中
100.0%
暂无批准数据
- University of Geneva researchers have created a revolutionary DNA-based drug delivery system that uses computer-like logic to target cancer cells with unprecedented precision. - The system employs a "two-factor authentication" approach, requiring both cancer markers to be present before activating the drug, significantly reducing damage to healthy cells. - Unlike traditional antibody-drug conjugates, the smaller DNA strands can penetrate tumors more effectively and carry multiple drug components simultaneously. - The technology represents a breakthrough in programmable medicine, with drugs that can "compute" and respond intelligently to biological signals within the body.